Nov 2026· Journal of immunotherapy· 0 citations· 24 references
Medicine
TL;DR
Nearly half of patients experienced at least one hospitalization with an irAE recorded as the main discharge diagnosis within 6 months after ICI initiation, underscoring the importance of monitoring and management to reduce patient and healthcare impact.
Abstract
Immune checkpoint inhibitors (ICIs) are effective for several tumor entities but cause immune-related adverse events (irAEs). These side effects may affect any organ and often lead to ICI discontinuation, hospitalization, long-term complications, or sequelae. To assess the burden of irAEs, this longitudinal observational study analyzed their incidence and the frequency of related hospitalizations using anonymized health claims data from a payer database covering 5.8 million insured individuals in Germany. Patients with hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), renal cancer, urothelial cancer, or skin cancer who started ICI therapy between 2017 and 2020 were selected using ICD-10 GM (International Statistical Classification of Diseases, German Modification) codes. The incidence of irAEs and related hospitalizations within 6 months was assessed using predefined ICD-10 codes in both inpatient and outpatient settings. A total of 6350 patients (mean age: 66.8 y) with NSCLC (n=4797), skin cancer (n=1266), HCC (n=1249), renal (n=1183), or urothelial cancer (n=656) initiated ICI therapy between 2017 and 2020. The incidence of any new-onset irAE was 31.4% (95% CI: 30.3%-32.6%). New-onset respiratory irAEs were the most common [11.7% (95% CI: 11.0%-12.5%)], followed by gastrointestinal irAEs (7.8%; 95% CI: 7.1%-8.5%). Skin cancer patients most frequently developed gastrointestinal irAEs, while other tumor types showed more respiratory irAEs. Using an inclusive definition that also captures exacerbations of pre-existing conditions, nearly half of patients experienced at least one hospitalization with an irAE recorded as the main discharge diagnosis within 6 months after ICI initiation. These findings underscore the importance of monitoring and management to reduce patient and healthcare impact.
Objective: Immune checkpoint inhibitors (ICIs) have improved cancer treatment outcomes but may cause immune-related adverse events (irAEs). Data regarding immunotherapy safety in elderly patients remain limited. This study aimed to evaluate irAE distribution, severity, and associated clinical factors in cancer patients...
In this cohort, irAE were highly prevalent and pembrolizumab-treated patients were predominant and chronic co-medications were not associated with the occurrence of irAE, however, the design of the study, short follow-up and limited sample size may have limited the detection of an effect.
Margot Vattaire-Hervé, C. Barbe, L. Bouazzi et al.· Journal of Oncology Pharmacy...· 0 citations
Immune checkpoint inhibitors (ICIs) have revolutionized oncologic treatment but are increasingly recognized to be associated with immune-related cardiovascular (CV) toxicities. While most epidemiological data were derived from Western populations, comprehensive real-world data from Asian cohorts remain limited. T...
K. Chen, W. Chang, Y. Chen et al.· European Heart Journal· 0 citations
OBJECTIVE
To evaluate the clinical efficacy of programmed cell death 1 (PD-1) inhibitors and identify risk factors for immune-related adverse reactions (irAEs) in patients with advanced non-small cell lung cancer (NSCLC).
METHODS
A retrospective analysis was performed on data from 224 advanced NSCLC patients treated...
Qian-Wen Gao, Lin Jin· American Journal of Cancer R...· 0 citations
Background:
Cardiovascular disease is the leading cause of non-cancer mortality in cancer survivors.1 Immune checkpoint inhibitors (ICIs) are associated with cardiovascular toxicity, but real-world burden across ICI classes and cancer types remains poorly characterized.2-4
Aims:
To characterize the incidence a...
Christabelle Junaidi, B. Schulte· Circulation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.